To determine how hFcγRIIIa contributes to immune effector functions, we performed ADCP and ADCC assays using anti-CD20 Rituximab-Fc3aV or anti-Her2 Trastuzumab-Fc3aV and CD20+ Raji cells or Her2high SK-BR-3 breast cancer cells as targets, respectively. This evidence concerns the gene ERBB2 and breast carcinoma.